RVPH
Income statement / Annual
Last year (2025), Reviva Pharmaceuticals Holdings Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Reviva Pharmaceuticals Holdings Inc.'s net income was -$19.86 T.
See Reviva Pharmaceuticals Holdings Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
02/29/2020 |
02/28/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$724.74 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$724.74 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.71 T
|
$22.91 M
|
$31.42 M
|
$18.95 M
|
$4.85 M
|
$295.15 K
|
$195.74 K
|
$946.30 K
|
| General & Administrative Expenses |
$8.49 T
|
$7.89 M
|
$8.08 M
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181.12 K
|
$175.58 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.49 T
|
$7.89 M
|
$8.08 M
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181.12 K
|
$175.58 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$0.00
|
| Operating Expenses |
$20.20 T
|
$30.80 M
|
$39.50 M
|
$24.31 M
|
$10.10 M
|
$2.43 M
|
$376.86 K
|
$1.12 M
|
| Cost And Expenses |
$0.00
|
-$30.80 M
|
$39.50 M
|
$24.31 M
|
$10.10 M
|
$2.43 M
|
$376.86 K
|
$1.12 M
|
| Interest Income |
$311.37 B
|
$361.37 K
|
$398.41 K
|
$182.80 K
|
$0.00
|
$105.18 K
|
$201.00
|
$0.00
|
| Interest Expense |
-$13.40 B
|
$18.50 K
|
$33.73 K
|
$182.80 K
|
$2.41 K
|
$1.45 M
|
$469.37 K
|
$557.68 K
|
| Depreciation & Amortization |
$0.00
|
$30.80 M
|
$39.50 M
|
$194.71 K
|
$591.00
|
$105.77 K
|
$846.00
|
$1.02 K
|
| EBITDA |
-$20.20 T |
-$29.88 M |
-$39.21 M |
-$24.11 M |
-$10.10 M |
-$2.33 M |
-$376.01 K |
-$1.12 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$354.02 B
|
$899.60 K
|
$259.75 K
|
-$11.91 K
|
$1.59 M
|
-$1.35 M
|
-$469.17 K
|
-$557.68 K
|
| Income Before Tax |
-$19.85 T
|
-$29.90 M
|
-$39.24 M
|
-$24.32 M
|
-$8.52 M
|
-$3.78 M
|
-$846.03 K
|
-$1.68 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$18.89 B
|
$19.51 K
|
$16.95 K
|
$20.78 K
|
$6.00 K
|
$800.00
|
$800.00
|
$800.00
|
| Net Income |
-$19.86 T
|
-$29.92 M
|
-$39.26 M
|
-$24.34 M
|
-$8.52 M
|
-$3.78 M
|
-$846.83 K
|
-$1.68 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.48 |
-18 |
-33 |
-29 |
-11.6 |
-24.8 |
-6.2 |
5.63 |
| EPS Diluted |
-5.48 |
-18 |
-33 |
-29 |
-11.6 |
-24.8 |
-6.2 |
5.63 |
| Weighted Average Shares Out |
$3.63 M
|
$1.66 M
|
$1.19 M
|
$975.82 K
|
$739.54 K
|
$153.08 K
|
$138.53 K
|
$101.98 K
|
| Weighted Average Shares Out Diluted |
$3.63 M
|
$1.66 M
|
$1.19 M
|
$975.82 K
|
$739.54 K
|
$153.08 K
|
$138.53 K
|
$101.98 K
|
| Link |
|
|
|
|
|
|
|
|
